A clinical study of short-term supraorbital nerve stimulation in the treatment of PHN in trigeminal nerve V1 distribution area

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052430

Enrollment

Unknown

Registered

2021-10-26

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Group A:pulsed radiofrequency

Group B:supraorbital nerve stimulation

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with postherpetic neuralgia on the head and face in the V1 distribution area of the trigeminal nerve, and the course of the disease is more than 1 month; 2. All patients have been treated with pregabalin and other drugs for more than half a month, and the effect is not good or the side effects are intolerable; 3. Visual analogue scale (VAS) >= 5 points; 4. All patients underwent trial block of supraorbital nerve.

Exclusion criteria

Exclusion criteria: 1. Serious heart, brain, liver, kidney and other diseases; 2. Patients with mental illness or mental illness cannot cooperate or tolerate surgery; 3. Intracranial space-occupying lesions or concurrent tumors; 4. Local infection or coagulation dysfunction.

Design outcomes

Primary

Measure	Time frame
Visual Analog Score;Pittsburgh Sleep Quality Index;	—

Secondary

Measure	Time frame
Drug dose;	—

Countries

China

Contacts

Public ContactLu Lijuan

the Drumtower Hospital, the Affiliated to Medical College of Nanjing University

932200932@qq.com+86 13372009709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026